Income Statement Provectus Biopharmaceuticals, Inc.

Stocks

PVCT

US74373P1084

Biotechnology & Medical Research

Market Closed - OTC Markets 13:49:27 2026-09-11 EDT			5-day change	1st Jan Change
0.0566 ^USD	+5.60%		-5.67%	+1.25%

08-13	Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-07	Provectus Biopharmaceuticals, Inc. Highlights Peer-Reviewed Study Demonstrating Opposing Mechanistic Effects Of Rose Bengal Sodium At The Same Dose	CI

1516ee67c5aef9d5e80f7af3c0f2.e9ojYDCGgUch08taxR9ec6flXdS-zz4RV_NtISt5swQ.TuhGFEDJ-XFjq7EF9UwKO-irMePUolkhZ8Q3exgO_nYM7msIQOTeLQykpA

Published financial data: PROVECTUS BIOPHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Revenues	-	989K	558K	617K	336K
Total Revenues	-	989K	558K	617K	336K
Cost of Goods Sold, Total	-	2.31M	1.7M	1.96M	1.81M
Gross Profit	-	-1.32M	-1.14M	-1.34M	-1.48M
Selling General & Admin Expenses, Total	2.12M	2.07M	1.36M	2.61M	3.31M
R&D Expenses	2.52M	-	-	-	54.11K
Other Operating Expenses, Total	4.64M	2.07M	1.36M	2.61M	3.37M
Operating Income	-4.64M	-3.39M	-2.5M	-3.95M	-4.84M
Interest Expense, Total	-962K	-164K	-216K	-239K	-210K
Interest And Investment Income	4	-	-	-	-
Net Interest Expenses	-962K	-164K	-216K	-239K	-210K
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	-5.6M	-3.55M	-2.71M	-4.19M	-5.05M
Legal Settlements	-	-	-387K	-577K	-450K
Other Unusual Items	63.09K	-	-	-	-
EBT, Incl. Unusual Items	-5.54M	-3.55M	-3.1M	-4.76M	-5.51M
Earnings From Continuing Operations	-5.54M	-3.55M	-3.1M	-4.76M	-5.51M
Net Income to Company	-5.54M	-3.55M	-3.1M	-4.76M	-5.51M
Minority Interest	-	-	-	-	74.27K
Net Income - (IS)	-5.54M	-3.55M	-3.1M	-4.76M	-5.43M
Preferred Dividend and Other Adjustments	-	-	-	-	-
Net Income to Common Incl Extra Items	-5.54M	-3.55M	-3.1M	-4.76M	-5.43M
Net Income to Common Excl. Extra Items	-5.54M	-3.55M	-3.1M	-4.76M	-5.43M
Per Share Items
Net EPS - Basic	-0.01	-0.01	-0.01	-0.01	-0.01
Basic EPS - Continuing Operations	-0.01	-0.01	-0.01	-0.01	-0.01
Basic Weighted Average Shares Outstanding	408M	419M	420M	420M	420M
Net EPS - Diluted	-0.01	-0.01	-0.01	-0.01	-0.01
Diluted EPS - Continuing Operations	-0.01	-0.01	-0.01	-0.01	-0.01
Diluted Weighted Average Shares Outstanding	408M	419M	420M	420M	420M
Normalized Basic EPS	-0.01	-0.01	-0	-0.01	-0.01
Normalized Diluted EPS	-0.01	-0.01	-0	-0.01	-0.01
Supplemental Items
EBITDA	-4.63M	-3.38M	-2.49M	-3.94M	-4.84M
EBITA	-4.64M	-3.39M	-2.5M	-3.95M	-4.84M
EBIT	-4.64M	-3.39M	-2.5M	-3.95M	-4.84M
EBITDAR	-4.54M	-3.32M	-2.44M	-3.89M	-4.79M
Normalized Net Income	-3.5M	-2.22M	-1.7M	-2.62M	-3.08M
Interest on Long-Term Debt	962K	-	46.19K	13.4K	8K
Supplemental Operating Expense Items
General and Administrative Expenses	2.04M	2.01M	1.31M	2.56M	3.26M
Research And Development Expense From Footnotes	2.61M	2.39M	1.75M	2M	1.9M
Net Rental Expense, Total	86.54K	63.07K	51.39K	51.45K	49.91K
Imputed Operating Lease Interest Expense	52.14K	42.04K	34.12K	31.68K	27.26K
Imputed Operating Lease Depreciation	34.4K	21.02K	17.27K	19.76K	22.66K
Stock-Based Comp., R&D Exp. (Total)	-	-	-	-	54.11K
Stock-Based Comp., G&A Exp. (Total)	23.69K	-	-	-	1.18M
Stock-Based Comp., Other (Total)	-	3.02K	2.85K	1.28M	-
Total Stock-Based Compensation	23.69K	3.02K	2.85K	1.28M	1.24M

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	683K	21.6K	76.58K	307K	251K
Total Cash And Short Term Investments	683K	21.6K	76.58K	307K	251K
Accounts Receivable, Total	-	-	476	-	-
Other Receivables	5.11K	394	-	-	-
Total Receivables	5.11K	394	476	-	-
Prepaid Expenses	330K	467K	338K	487K	244K
Deferred Tax Assets Current	-	-	-	-	1.6K
Restricted Cash	2.42M	1.41M	950K	182K	-
Other Current Assets, Total	-	-	-	-	71.4K
Total Current Assets	3.44M	1.9M	1.36M	977K	568K
Gross Property Plant And Equipment	163K	240K	195K	148K	250K
Accumulated Depreciation	-91.18K	-102K	-111K	-118K	-120K
Net Property Plant And Equipment	71.4K	138K	84.05K	29.49K	130K
Other Intangibles, Total	-	-	-	-	-
Other Long-Term Assets, Total	-	-	-	-	-
Total Assets	3.51M	2.04M	1.45M	1.01M	698K
Liabilities
Accounts Payable, Total	1.29M	2.09M	1.68M	1.11M	716K
Accrued Expenses, Total	2.02M	2.48M	3.39M	2.35M	3.31M
Short-term Borrowings	238K	239K	278K	206K	218K
Current Portion of Long-Term Debt	1.46M	1.83M	2.68M	2.95M	2.61M
Current Portion of Leases	45.62K	44.42K	48.08K	25.3K	48.08K
Unearned Revenue Current, Total	2.5M	1.51M	953K	336K	-
Other Current Liabilities	150K	-	-	-	-
Total Current Liabilities	7.7M	8.19M	9.02M	6.98M	6.9M
Long-Term Debt	-	-	-	-	23.62K
Long-Term Leases	-	73.38K	25.3K	-	79.22K
Total Liabilities	7.7M	8.27M	9.04M	6.98M	7M
Preferred Stock Convertible	21.59K	22.12K	22.73K	14.06K	15.14K
Total Preferred Equity	21.59K	22.12K	22.73K	14.06K	15.14K
Common Stock, Total	419K	419K	420K	420K	420K
Additional Paid In Capital	241M	243M	245M	251M	256M
Retained Earnings	-246M	-250M	-253M	-257M	-263M
Comprehensive Income and Other	-34.47K	-35.68K	-60.16K	-60.74K	-60.19K
Total Common Equity	-4.21M	-6.25M	-7.62M	-5.97M	-6.31M
Minority Interest	-	-	-	-9.89K	-3.98K
Total Equity	-4.19M	-6.23M	-7.59M	-5.97M	-6.3M
Total Liabilities And Equity	3.51M	2.04M	1.45M	1.01M	698K
Supplemental Items
ECS Total Shares Outstanding on Filing Date	419M	419M	420M	420M	420M
ECS Total Common Shares Outstanding	419M	419M	420M	420M	420M
Book Value / Share	-0.01	-0.01	-0.02	-0.01	-0.02
Tangible Book Value	-4.21M	-6.25M	-7.62M	-5.97M	-6.31M
Tangible Book Value Per Share	-0.01	-0.01	-0.02	-0.01	-0.02
Total Debt	1.74M	2.18M	3.03M	3.18M	2.98M
Net Debt	1.06M	2.16M	2.95M	2.88M	2.73M
Debt Equivalent Oper. Leases	692K	505K	411K	412K	399K
Minority Interest, Total (Incl. Fin. Div)	-	-	-	-9.89K	-3.98K
Account Code - Inventory Valuation	-	-	-	3	3
Machinery, Total	123K	123K	123K	123K	-
Full Time Employees	4	4	4	6	6

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-5.54M	-3.55M	-3.1M	-4.76M	-5.43M
Depreciation & Amortization - CF	12.86K	10.9K	8.92K	7.16K	1.86K
Amortization of Goodwill and Intangible Assets - (CF)	-	-	-	-	-
Depreciation & Amortization, Total	12.86K	10.9K	8.92K	7.16K	1.86K
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
Stock-Based Compensation (CF)	23.69K	3.02K	2.85K	1.28M	1.24M
Other Operating Activities, Total	18.16K	52.88K	45.1K	47.4K	-26.14K
Change In Accounts Receivable	-	-	-82	476	-
Change In Accounts Payable	331K	807K	-418K	-569K	-390K
Change in Unearned Revenues	2.5M	-989K	-558K	-617K	-336K
Change in Other Net Operating Assets	1.64M	628K	1.45M	1.33M	1.62M
Cash from Operations	-1.01M	-3.04M	-2.57M	-3.28M	-3.33M
Capital Expenditure	-	-	-	-	-
Cash from Investing	-	-	-	-	-
Short Term Debt Issued, Total	-	1.63M	2.48M	-	-
Long-Term Debt Issued, Total	3.16M	-	-	2.85M	2.51M
Total Debt Issued	3.16M	1.63M	2.48M	2.85M	2.51M
Short Term Debt Repaid, Total	-248K	-260K	-283K	-305K	-273K
Long-Term Debt Repaid, Total	-	-	-	-100K	-
Total Debt Repaid	-248K	-260K	-283K	-405K	-273K
Issuance of Common Stock	962K	-	-	-	-
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	150K	-	-	300K	850K
Cash from Financing	4.02M	1.37M	2.19M	2.75M	3.09M
Foreign Exchange Rate Adjustments	-1.03K	-1.6K	-24.48K	-847	550
Net Change in Cash	3.01M	-1.68M	-405K	-537K	-238K
Supplemental Items
Cash Interest Paid	-	-	-	-	4.3K
Levered Free Cash Flow	-6.94M	-1.2M	-1.16M	-2.93M	-1.34M
Unlevered Free Cash Flow	-6.34M	-1.1M	-1.03M	-2.78M	-1.2M
Change In Net Working Capital	3.48M	-1.01M	-524K	1.61M	-584K
Net Debt Issued / Repaid	2.91M	1.37M	2.19M	2.45M	2.24M

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-141.4	-76.37	-89.58	-200.92	-355.41
Return on Total Capital	65.53	65.34	36.27	67.1	99.13
Return On Equity %	32.21	68.26	44.88	70.22	89.72
Return on Common Equity	32.19	67.97	44.74	70.09	88.4
Margin Analysis
Gross Profit Margin %	-	-133.6	-204.69	-216.87	-439.03
SG&A Margin	-	209.26	243.28	422.56	986.16
EBITDA Margin %	-	-341.75	-446.37	-638.27	-1.44K
EBITA Margin %	-	-342.86	-447.97	-639.43	-1.44K
EBIT Margin %	-	-342.86	-447.97	-639.43	-1.44K
Income From Continuing Operations Margin %	-	-359.41	-556.16	-771.65	-1.64K
Net Income Margin %	-	-359.41	-556.16	-771.65	-1.62K
Net Avail. For Common Margin %	-	-359.41	-556.16	-771.65	-1.62K
Normalized Net Income Margin	-	-224.63	-304.21	-423.85	-917.82
Levered Free Cash Flow Margin	-	-121.52	-208.09	-475.46	-397.55
Unlevered Free Cash Flow Margin	-	-111.17	-183.86	-451.24	-358.43
Asset Turnover
Asset Turnover	-	0.36	0.32	0.5	0.39
Fixed Assets Turnover	-	9.44	5.02	10.87	4.22
Receivables Turnover (Average Receivables)	-	-	1.28K	-	-
Short Term Liquidity
Current Ratio	0.45	0.23	0.15	0.14	0.08
Quick Ratio	0.09	0	0.01	0.04	0.04
Operating Cash Flow to Current Liabilities	-0.13	-0.37	-0.29	-0.47	-0.48
Days Sales Outstanding (Average Receivables)	-	-	0.28	-	-
Average Days Payable Outstanding	-	267.13	404.91	260.39	183.61
Long Term Solvency
Total Debt/Equity	-41.65	-35.08	-39.85	-53.35	-47.26
Total Debt / Total Capital	-71.38	-54.03	-66.26	-114.38	-89.61
LT Debt/Equity	-	-1.18	-0.33	-	-1.63
Long-Term Debt / Total Capital	-	-1.81	-0.55	-	-3.09
Total Liabilities / Total Assets	219.18	405.73	624.1	693.21	1K
EBIT / Interest Expense	-4.83	-20.72	-11.56	-16.51	-23.03
EBITDA / Interest Expense	-4.72	-20.26	-11.28	-16.26	-22.78
(EBITDA - Capex) / Interest Expense	-4.72	-20.26	-11.28	-16.26	-22.78
Total Debt / EBITDA	-0.38	-0.66	-1.24	-0.82	-0.62
Net Debt / EBITDA	-0.23	-0.65	-1.21	-0.74	-0.57
Total Debt / (EBITDA - Capex)	-0.38	-0.66	-1.24	-0.82	-0.62
Net Debt / (EBITDA - Capex)	-0.23	-0.65	-1.21	-0.74	-0.57
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	-	-43.61	10.66	-45.54
Gross Profit, 1 Yr. Growth %	-	-47.55	-13.6	17.24	10.25
EBITDA, 1 Yr. Growth %	-1.41	-26.97	-12.91	58.23	22.93
EBITA, 1 Yr. Growth %	-1.42	-26.93	-12.93	57.95	22.76
EBIT, 1 Yr. Growth %	-5.98	-26.93	-12.93	57.95	22.76
Earnings From Cont. Operations, 1 Yr. Growth %	-17.04	-35.83	-12.74	53.53	15.6
Net Income, 1 Yr. Growth %	-17.04	-35.83	-12.74	53.53	14.76
Normalized Net Income, 1 Yr. Growth %	-16.14	-36.55	-10.5	54.18	19.28
Diluted EPS Before Extra, 1 Yr. Growth %	-20.09	-37.55	-12.76	53.43	14.62
Accounts Receivable, 1 Yr. Growth %	-	-	20.81	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-56.86	93.37	-39.13	-64.92	339.61
Total Assets, 1 Yr. Growth %	496.29	-42.01	-28.88	-30.55	-30.68
Tangible Book Value, 1 Yr. Growth %	-86.07	48.51	21.84	-21.57	5.7
Common Equity, 1 Yr. Growth %	-86.07	48.51	21.84	-21.57	5.7
Cash From Operations, 1 Yr. Growth %	-75.2	200.15	-15.44	27.69	1.28
Levered Free Cash Flow, 1 Yr. Growth %	-755.39	-82.68	32.51	152.83	-54.46
Unlevered Free Cash Flow, 1 Yr. Growth %	-394.63	-82.65	32.56	171.58	-56.74
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	-	-21.01	-22.37
Gross Profit, 2 Yr. CAGR %	-	-	-32.69	0.64	13.69
EBITDA, 2 Yr. CAGR %	-8.1	-15.14	-26.66	17.39	39.47
EBITA, 2 Yr. CAGR %	-8.1	-15.13	-26.63	17.27	39.25
EBIT, 2 Yr. CAGR %	-13.24	-17.11	-26.63	17.27	39.25
Earnings From Cont. Operations, 2 Yr. CAGR %	-10.55	-27.04	-25.17	15.74	33.22
Net Income, 2 Yr. CAGR %	-10.55	-27.04	-25.17	15.74	32.32
Normalized Net Income, 2 Yr. CAGR %	-14.13	-27.06	-30.39	17.47	34.84
Diluted EPS Before Extra, 2 Yr. CAGR %	-12.95	-29.36	-26.19	15.7	32.2
Net Property, Plant and Equip., 2 Yr. CAGR %	-46.85	-8.67	8.5	-53.79	24.19
Total Assets, 2 Yr. CAGR %	54.24	85.95	-35.78	-29.72	-30.62
Tangible Book Value, 2 Yr. CAGR %	-58.38	-54.51	34.52	-2.24	-8.95
Common Equity, 2 Yr. CAGR %	-58.19	-54.51	34.52	-2.24	-8.95
Cash From Operations, 2 Yr. CAGR %	-59.54	-13.72	59.32	3.91	13.72
Capital Expenditures, 2 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 2 Yr. CAGR %	1.4	6.53	-59.11	83.03	7.3
Unlevered Free Cash Flow, 2 Yr. CAGR %	4.18	-28.51	-59.78	89.74	8.39
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-	-	-30.22
Gross Profit, 3 Yr. CAGR %	-	-	-	-19.01	3.75
EBITDA, 3 Yr. CAGR %	-14.26	-14.88	-19.06	-5.23	19.21
EBITA, 3 Yr. CAGR %	-14.24	-14.86	-19.04	-5.26	19.07
EBIT, 3 Yr. CAGR %	-16.7	-18.07	-20.31	-5.26	19.07
Earnings From Cont. Operations, 3 Yr. CAGR %	-12.09	-19.92	-22.55	-4.92	15.7
Net Income, 3 Yr. CAGR %	-12.09	-19.92	-22.55	-4.92	15.17
Normalized Net Income, 3 Yr. CAGR %	-14.55	-22.37	-25.93	-9.26	17.62
Diluted EPS Before Extra, 3 Yr. CAGR %	-13.99	-22.07	-24.21	-5.8	15.1
Net Property, Plant and Equip., 3 Yr. CAGR %	-0.5	-18.26	-20.22	-25.53	-2.08
Total Assets, 3 Yr. CAGR %	20.9	11.32	34.97	-34.08	-30.04
Tangible Book Value, 3 Yr. CAGR %	-38.75	-36.4	-36.83	12.38	0.34
Common Equity, 3 Yr. CAGR %	-37.71	-36.2	-36.83	12.38	0.34
Cash From Operations, 3 Yr. CAGR %	-42.04	-21.09	-14.3	47.99	3.03
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 3 Yr. CAGR %	25.67	-43.74	3.1	-24.95	15.12
Unlevered Free Cash Flow, 3 Yr. CAGR %	29.92	-42.69	-21.89	-23.98	15.91
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-27.95	-23.18	-19.45	-6.39	0.62
EBITA, 5 Yr. CAGR %	-27.91	-23.15	-19.43	-6.41	0.57
EBIT, 5 Yr. CAGR %	-28.31	-23.94	-20.82	-8.54	-0.37
Earnings From Cont. Operations, 5 Yr. CAGR %	-25.68	-23.44	-17.58	-7.21	-3.79
Net Income, 5 Yr. CAGR %	-25.68	-23.44	-17.58	-7.21	-4.05
Normalized Net Income, 5 Yr. CAGR %	-25.51	-23.64	-21.28	-11.24	-5.87
Diluted EPS Before Extra, 5 Yr. CAGR %	-35.7	-25.39	-19.09	-8.73	-5.32
Net Property, Plant and Equip., 5 Yr. CAGR %	-0.18	9.79	3.01	-34.93	-4.77
Total Assets, 5 Yr. CAGR %	-8.94	-9.93	-6.13	-7.39	3.43
Tangible Book Value, 5 Yr. CAGR %	27.94	-11.62	-16.1	-24.47	-26.88
Common Equity, 5 Yr. CAGR %	3.94	-9	-15.25	-24.33	-26.88
Cash From Operations, 5 Yr. CAGR %	-45.94	-21.72	-13.15	-11.91	-4.03
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	-
Levered Free Cash Flow, 5 Yr. CAGR %	-15.68	-28.1	-19.79	-15.35	4.76
Unlevered Free Cash Flow, 5 Yr. CAGR %	-17.19	-28.79	-18.72	-13.77	-10.95